Drug intelligence / Profile preview

heparin + insulin lispro

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Subcutaneous

Overview

A combination of heparin and insulin lispro used primarily for treating subcutaneous insulin resistance syndrome. This combination helps improve insulin absorption in patients who don't respond adequately to standard subcutaneous insulin therapy. The mixture is typically administered via continuous subcutaneous insulin infusion (insulin pump) and has been shown to effectively reduce blood glucose levels in patients with poor glycemic control despite high doses of standard insulin therapy.

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on heparin + insulin lispro.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on heparin + insulin lispro.

Explore the full profile